Quotables
"There is practically no chance communications space satellites will be used to provide better telephone, telegraph, television, or radio service inside the United States."
T. Craven, FCC Commissioner ; 1961
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107363 | IMMUNOGEN AGAINST CAMPYLOBACTER INFECTION The invention relates to the use of Campylobacter jejuni gene product jlpA and immunogenic fragments of jlpA as a component of a pharmaceutical formulation capable of eliciting an anti-Campylobacter jejuni immune response. The invention also relates to a m... | 05/03/2012 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110206683 | PRESERVATION MIXTURE AND USE THEREOF The invention relates to a preservation composition, a formulation comprising a preservation mixture of glutamate, a saccharide, and a polymer. Said preservation mixture is advantageously used for the preservation of a biological compound.... | 08/25/2011 |
| 20110182857 | Delivery of Drugs to Mucosal Surfaces Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an ext... | 07/28/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110142881 | TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular ... | 06/16/2011 |
| 20110135679 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a... | 06/09/2011 |
| 20100285064 | ADJUVANT COMPOSITION FOR VACCINE The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.... | 11/11/2010 |
| 20100272756 | GRAM POSITIVE BACTERIA PREPARATIONS FOR THE TREATMENT OF DISEASES COMPRISING AN IMMUNE DYSREGULATION This application relates to compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intracellular bacteria for treatment of disorders comprising an immune dysregulation in humans and animals.... | 10/28/2010 |
| 20100266534 | Human Lymphocyte Vaccine Adjuvant The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent... | 10/21/2010 |
| 20100247537 | ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als... | 09/30/2010 |
| 20100166840 | LIPOSOME HAVING LIPID MEMBRANE CONTAINING BACTERIAL CELL COMPONENT The object is to provide a liposome by which a bacterial cell component insoluble in water and an organic solvent (e.g., BCG-CW) can be pharmaceutically prepared in a form applicable to a living body (i.e., a form in which the bacterial cell component can be dispersed i... | 07/01/2010 |
| 20100158952 | MICROORGANISMS OR FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the... | 06/24/2010 |
| 20100112078 | POLYMER PARTICLES BASED VACCINE The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wher... | 05/06/2010 |
| 20100028448 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprisin... | 02/04/2010 |
| 20090297559 | USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pu... | 12/03/2009 |
| 20090214537 | Serum Resistance Factors of Gram Positive Bacteria A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.... | 08/27/2009 |
| 20090181054 | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conju... | 07/16/2009 |
| 20090169636 | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adju... | 07/02/2009 |
| 20090155330 | Vaccine Delivery via Microneedle Arrays A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another ... | 06/18/2009 |
| 20090110699 | Antigen-Adjuvant Compositions and Methods Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine com... | 04/30/2009 |
| 20090074816 | TISSUE TARGETED ANTIGENIC ACTIVATION OF THE IMMUNE RESPONSE TO CANCERS The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formu... | 03/19/2009 |
| 20090010964 | Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered w... | 01/08/2009 |
